In addition, therapeutic strategies targeting B cells or their activator molecules such as BLyS have been shown to alter T cell functions as observed in pemphigus patients: treatment with the anti-CD20-antibody RTX resulted in a significant decrease in Dsg-specific, IL-4- and IFNγ-producing autoreactive T cells in the peripheral blood which is ascribed to the deletion of B cells that enable T-cell activation as critical APC [108]. The gene discussed is DSG1; the disease is pemphigus.